Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route

Current Pharmaceutical Design

Volumn 23, Issue 17, 2017, Pages 2504-2531

  Choudhury, Hira ^a   Gorain, Bapi ^b   Chatterjee, Bappaditya ^c   Mandal, Uttam K ^c   Sengupta, Pinaki ^c   Tekade, Rakesh K ^a,d  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b LINCOLN UNIVERSITY COLLEGE   (Malaysia)

^c INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA   (Malaysia)

^d NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

Author keywords

Carbon nanotubes; Hydrophobicity; Oral delivery; Pharmacodynamics; Pharmacokinetics; Routes of administration

Indexed keywords

ALPHA TOCOPHEROL; ARTEETHER; CANDESARTAN; CELECOXIB; CHLORAMBUCIL; COSURFACTANT; DAPSONE; DOCETAXEL; DOMPERIDONE; EFAVIRENZ; EVODIAMINE; FISETIN; GRANISETRON; HEPTADECANOIC ACID; IMIPRAMINE; MELPHALAN; NITRENDIPINE; OIL; OLANZAPINE; OLMESARTAN; PACLITAXEL; PANAX NOTOGINSENG EXTRACT; RESVERATROL; RISPERIDONE; SILYMARIN; SURFACTANT; TRAMADOL; UBIDECARENONE; UNINDEXED DRUG; ZIPRASIDONE; DRUG; NANOMATERIAL;

AQUEOUS SOLUTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STRUCTURE; GERIATRIC PATIENT; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; NANOEMULSION; NONHUMAN; ORAL DRUG ADMINISTRATION; PEDIATRICS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION; ADMINISTRATION AND DOSAGE; CHEMISTRY; EMULSION;

DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS;

EID: 84994899023     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161201143600     Document Type: Review

References (200)

1. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011; 420: 1-10.
2. Benet LZ. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci 2013; 102: 34-42.
3. Idkaidek NM. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi Pharm J 2014; 22: 79-81.
4. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drugrelease kinetics. J Microencapsul 2009; 26: 287-296.
5. Dahan A, Beig A, Lindley D, Miller JM. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one. Adv Drug Deliv Rev 2016; 101: 99-107.
6. Daeihamed M, Dadashzadeh S, Haeri A, Akhlaghi M. Potential of liposomes for enhancement of oral drug absorption. Curr Drug Deliv 2017; 14: 289-303.
7. Shakeri A, Sahebkar A. Opinion paper: nanotechnology: A successful approach to improve oral bioavailability of phytochemicals. Recent Pat Drug Deliv Formul 2016; 10: 4-6.
8. Gajbhiye V, Kumar PV, Tekade RK, Jain N. PEGylated PPI dendritic architectures for sustained delivery of H 2 receptor antagonist. Eur J Med Chem 2009; 44: 1155-66.
9. Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2008; 109: 49-87.
10. Tekade RK, Dutta T, Jain N, Gajbhiye V, Jain NK. Simultaneous spectrophotometric estimation of methotrexate and all-trans retinoic acid in mixture. Asian J Chem 2009; 21: 5145.
11. Tambe V, Thakkar S, Raval N, Sharma D, Kalia K, Tekade R. Surface Engineered dendrimers in sirna delivery and gene silencing. Curr Pharm Des 2017 [Epub ahead of print].
12. Singh Dhakad R, Kumar Tekade R, Kumar Jain N. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr Drug deliv 2013; 10: 477-491.
13. Tekade RK, Chougule MB. Formulation development and evaluation of hybrid nanocarrier for cancer therapy: taguchi orthogonal array based design. BioMed Res Int 2013; 2013: 712678.
14. Tekade RK, D'Emanuele A, Elhissi A, et al. Extraction and RPHPLC determination of taxol in rat plasma, cell culture and quality control samples. J Biomed Res 2013; 27: 394-405.
15. Jain S, Kesharwani P, Tekade RK, Jain NK. One platform comparison of solubilization potential of dendrimer with some solubilizing agents. Drug Develop Indus Pharm 2015; 41: 722-7.
16. Mody N, Tekade RK, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. Aaps Pharmscitech 2014; 15: 388-99.
17. A Sharma P, Maheshwari R, Tekade M, Kumar Tekade R. Nanomaterial based approaches for the diagnosis and therapy of cardiovascular diseases. Curr Pharm Des 2015; 21: 4465-78.
18. Chopdey PK, Tekade RK, Mehra NK, Mody N, Jain NK. Glycyrrhizin conjugated dendrimer and multi-walled carbon nanotubes for liver specific delivery of doxorubicin. J Nanosci Nanotechnol 2015; 15: 1088-100.
19. Maheshwari R, Tekade M, A Sharma P, Kumar Tekade R. Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders. Curr Pharm Des 2015; 21: 4427-40.
20. Kumar TR, GS Maheshwari R, Sharma P, Tekade M, Singh CA. siRNA therapy, challenges and underlying perspectives of dendrimer as delivery vector. Curr Pharm Des 2015; 21: 4614-36.
21. Tekade RK, Tekade M, Kumar M, Chauhan AS. Dendrimerstabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. Pharm Res 2015; 32: 910-28.
22. Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Albumin-chitosan hybrid onconase nanocarriers for mesothelioma therapy. In: ed.^eds. American Association for Cancer Res 2015; 75 (15 suppl).
23. Tekade RK. Editorial: Contemporary siRNA Therapeutics and the Current State-of-Art. In: ed.^eds. 2014.
24. Maheshwari RG, Thakur S, Singhal S, Patel RP, Tekade M, Tekade RK. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin. Sci Adv Mater 2015; 7: 1163-76.
25. Mansuri S, Kesharwani P, Tekade RK, Jain NK. Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole. Eur J Pharm Biopharm 2016; 102: 202-13.
26. Mansuri S, Kesharwani P, Jain K, Tekade RK, Jain N. Mucoadhesion: a promising approach in drug delivery system. Reactive Functional Polym 2016; 100: 151-72.
27. Ghanghoria R, Tekade RK, Mishra AK, Chuttani K, Jain NK. Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel. Nanomed 2016; 11: 797-816.
28. Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Controlled Release 2014; 194: 238-56.
29. Tekade RK, Youngren-Ortiz SR, Yang H, Haware R, Chougule MB. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol Pharm 2014; 11: 3671-83.
30. Tekade R, Xu L, Hao G, et al. A facile preparation of radioactive gold nanoplatforms for potential theranostic agents of cancer. J Nuclear Medi 2014; 55: 1047-7.
31. Tekade RK, Tekade M, Kesharwani P, D’Emanuele A. RNAicombined nano-chemotherapeutics to tackle resistant tumors. Drug Discov Today 2016; 21: 1761-74.
32. Dua K, Shukla SD, Tekade RK, Hansbro PM. Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases? Drug Deliv Trans Res 2016: 1-9.
33. Moeendarbari S, Tekade R, Mulgaonkar A, et al. Theranostic nanoseeds for efficacious internal radiation therapy of unresectable solid tumors. Scientific Rep 2016; 6.
34. Huang R-FS, Wei Y-J, Inbaraj BS, Chen B-H. Inhibition of colon cancer cell growth by nanoemulsion carrying gold nanoparticles and lycopene. Int J Nanomed 2015; 10: 2823.
35. Ali A, Mekhloufi G, Huang N, Agnely F. β-lactoglobulin stabilized nanemulsions—Formulation and process factors affecting droplet size and nanoemulsion stability. Int J Pharm 2016; 500: 291-304.
36. Gorain B, Choudhury H, Tekade RK, Karan S, Jaisankar P, Pal TK. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. Regulatory Toxicol Pharmacol 2016; 82: 20-31.
37. Zhou Z, Kennell C, Lee JY, Leung YK, Tarapore P. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomed Nanotechnol Biol Med 2016.
38. Damitz R, Chauhan A. Parenteral emulsions and liposomes to treat drug overdose. Adv Drug Deliv Rev 2015; 90: 12-23.
39. Skorkowska-Telichowska K, Hasiewicz-Derkacz K, Gębarowski T, et al. Emulsions made of oils from seeds of GM flax protect V79 cells against oxidative stress. Oxidat Med Cell Longev 2016; 2016: 7510759.
40. Prajapati RN, Tekade RK, Gupta U, Gajbhiye V, Jain NK. Dendimer-mediated solubilization, formulation development and in vitro− in vivo assessment of piroxicam. Molr Pharm 2009; 6: 940-50.
41. Gajbhiye V, Vijayaraj Kumar P, Kumar Tekade R, Jain N. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Des 2007; 13: 415-29.
42. Perazzo A, Preziosi V, Guido S. Phase inversion emulsification: Current understanding and applications. Adv Colloid Interface Sci 2015; 222: 581-99.
43. Kaizu K, Alexandridis P. Effect of surfactant phase behavior on emulsification. J Colloid Interface Sci 2016; 466: 138-149.
44. Gutiérrez J, González C, Maestro A, Sole I, Pey C, Nolla J. Nanoemulsions: New applications and optimization of their preparation. Curr Opi Colloid Interface Sci 2008; 13: 245-51.
45. McClements DJ. Nanoemulsion-based oral delivery systems for lipophilic bioactive components: nutraceuticals and pharmaceuticals. Therapeut Deliv 2013; 4: 841-57.
46. Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research—opportunities and challenges in targeted cancer therapy. Aaps Pharmscitech 2014; 15: 694-708.
47. Pawar KR, Babu RJ. Lipid materials for topical and transdermal delivery of nanoemulsions. Critic Rev™ Therapeut Drug Carrier Systems 2014; 31.
48. Dellacasa E, Pastorino L, Scanarotti C, et al. Peroxidated olive oil nanoemulsion for cancer targeted therapy. In: ed.^eds., Engineering in Medicine and Biology Society (EMBC) 2015 37th Annual Int Conference of the IEEE. IEEE 2015; pp. 2580-2583.
49. Lu Y, Qi J, Wu W. Absorption, disposition and pharmacokinetics of nanoemulsions. Curr Drug Metabol 2012; 13: 396-417.
50. Jaiswal M, Dudhe R, Sharma P. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech 2015; 5: 123-7.
51. Soni N, Soni N, Pandey H, Maheshwari R, Kesharwani P, Tekade RK. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J Colloid Interface Sci 2016; 481: 107-16.
52. Comfort C, Garrastazu G, Pozzoli M, Sonvico F. Opportunities and challenges for the nasal administration of nanoemulsions. Curr Topics Med Chem 2015; 15: 356-8.
53. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK. Surface-engineered dendrimers for dual drug delivery: a receptor upregulation and enhanced cancer targeting strategy. J Drug Targeting 2008; 16: 758-72.
54. Lee HS, Morrison ED, Frethem CD, Zasadzinski JA, McCormick AV. Cryogenic electron microscopy study of nanoemulsion formation from microemulsions. Langmuir 2014; 30: 10826-33.
55. Shakeel F, Ramadan W. Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions. Colloids Surf B Biointerfaces 2010; 75: 356-62.
56. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retinal Eye Res 2002; 21: 15-34.
57. Lu W-C, Chiang B-H, Huang D-W, Li P-H. Skin permeation of dlimonene-based nanoemulsions as a transdermal carrier prepared by ultrasonic emulsification. Ultrasonics Sonochem 2014; 21: 826-32.
58. Wang Y, Feng Y, Lu LN, et al. The effects of different lipid emulsions on the lipid profile, fatty acid composition, and antioxidant capacity of preterm infants: A double-blind, randomized clinical trial. Clin Nutr 2016; 35: 1023-31.
59. Yukuyama M, Ghisleni D, Pinto T, Bou_Chacra N. Nanoemulsion: process selection and application in cosmetics-a review. Int J Cosmetic Sci 2016; 38: 13-24.
60. Kotta S, Khan AW, Pramod K, Ansari SH, Sharma RK, Ali J. Exploring oral nanoemulsions for bioavailability enhancement of poorly water-soluble drugs. Exp Opin Drug Deliv 2012; 9: 585-98.
61. Souto EB. Lipid nanocarriers in cancer diagnosis and therapy. ISmithers 2011.
62. Warisnoicharoen W, Lansley A, Lawrence M. Nonionic oil-inwater microemulsions: the effect of oil type on phase behaviour. Int J Pharm 2000; 198: 7-27.
63. Sapra B, Thatai P, Bhandari S, Sood J, Jindal M, Tiwary A. A critical appraisal of microemulsions for drug delivery: part I. Therapeut Deliv 2013; 4: 1547-64.
64. Constantinides PP, Tustian A, Kessler DR. Tocol emulsions for drug solubilization and parenteral delivery. Adv Drug Deliv Rev 2004; 56: 1243-55.
65. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007; 345: 9-25.
66. Date AA, Nagarsenker M. Parenteral microemulsions: an overview. Int J Pharm 2008; 355: 19-30.
67. Azeem A, Rizwan M, Ahmad FJ, et al. Nanoemulsion components screening and selection: a technical note. Aaps Pharmscitech 2009; 10: 69-76.
68. Gupta R, Shea J, Scaife C, Shurlygina A, Rapoport N. Polymeric micelles and nanoemulsions as drug carriers: therapeutic efficacy, toxicity, and drug resistance. J Controlled Release 2015; 212: 70-7.
69. Musa SH, Basri M, Masoumi HRF, et al. Formulation optimization of palm kernel oil esters nanoemulsion-loaded with chloramphenicol suitable for meningitis treatment. Colloids Surf B Biointerfaces 2013; 112: 113-9.
70. Đorđević SM, Radulović TS, Cekić ND, et al. Experimental design in formulation of diazepam nanoemulsions: physicochemical and pharmacokinetic performances. J Pharm Sci 2013; 102: 4159-72.
71. Hu J, Chen D, Jiang R, Tan Q, Zhu B, Zhang J. Improved absorption and in vivo kinetic characteristics of nanoemulsions containing evodiamine-phospholipid nanocomplex. Int J Nanomed 2014; 9: 4411.
72. Moreno MA, Ballesteros MP, Frutos P. Lecithin_based oil_in_water microemulsions for parenteral use: Pseudoternary phase diagrams, characterization and toxicity studies. J Pharm Sci 2003; 92: 1428-37.
73. Rowe RC, Sheskey PJ, Quinn M. Handbook of pharmaceutical excipients-7th edition. Pharm Dev Technol 2013; 18: 544.
74. Lopes LB. Overcoming the cutaneous barrier with microemulsions. Pharmaceutics 2014; 6: 52-77.
75. Sapra B, Thatai P, Bhandari S, Sood J, Jindal M, Tiwary AK. A critical appraisal of microemulsions for drug delivery: part II. Therapeut Deliv 2014; 5: 83-94.
76. Oliveira JS, Aguiar TA, Mezadri H, dos Santos ODH. Attainment of hydrogel-thickened nanoemulsions with tea tree oil (Melaleuca alternifolia) and retinyl palmitate. African J Biotechnol 2011; 10: 13014-8.
77. Schwarz JS, Weisspapir MR, Friedman DI. Enhanced transdermal delivery of diazepam by submicron emulsion (SME) creams. Pharm Res 1995; 12: 687-92.
78. Schwarz JC, Klang V, Karall S, Mahrhauser D, Resch GP, Valenta C. Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir. Int J Pharm 2012; 435: 69-75.
79. Pawar VK, Panchal SB, Singh Y, et al. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J Controlled Release 2014; 196: 295-306.
80. Schoellhammer CM, Blankschtein D, Langer R. Skin permeabilization for transdermal drug delivery: recent advances and future prospects. Expert Opin Drug Deliv 2014; 11: 393-407.
81. Mahmood S, Taher M, Mandal UK. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application. Int J Nanomed 2014; 9: 4331.
82. Tamilvanan S, Schmidt S, Müller RH, Benita S. In vitro adsorption of plasma proteins onto the surface (charges) modified-submicron emulsions for intravenous administration. Eur J Pharm Biopharm 2005; 59: 1-7.
83. Li X, Du L, Wang C, Liu Y, Mei X, Jin Y. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals. Die Pharmazie-An Int J Pharm Sci 2011; 66: 479-83.
84. Lalani J, Baradia D, Lalani R, Misra A. Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. Pharm Develop Technol 2015; 20: 992-1001.
85. Mahajan HS, Mahajan MS, Nerkar PP, Agrawal A. Nanoemulsionbased intranasal drug delivery system of saquinavir mesylate for brain targeting. Drug Deliv 2014; 21: 148-54.
86. Kumar M, Misra A, Babbar A, Mishra A, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358: 285-91.
87. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009; 379: 146-57.
88. Cao X, Luo J, Gong T, Zhang Z-R, Sun X, Fu Y. Coencapsulated doxorubicin and bromotetrandrine lipid nanoemulsions in reversing multidrug resistance in breast cancer in vitro and in vivo. Molr Pharm 2014; 12: 274-86.
89. Ganta S, Singh A, Kulkarni P, et al. EGFR targeted theranostic nanoemulsion for image-guided ovarian cancer therapy. Pharm Res 2015; 32: 2753-63.
90. Huang CW, Kearney V, Moeendarbari S, et al. Hollow gold nanoparticals as biocompatible radiosensitizer: an in vitro proof of concept study. J Nano Res 2015; 32: 106.
91. Muzammil Afzal S, Naidu VM, Harishankar N, Kishan V. Albumin anchored docetaxel lipid nanoemulsion for improved targeting efficiency-preparation, characterization, cytotoxic, antitumor and in vivo imaging studies. Drug Deliv 2016; 23: 1355-63.
92. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007; 337: 1-24.
93. Anton N, Vandamme TF. The universality of low-energy nanoemulsification. Int J Pharm 2009; 377: 142-7.
94. Flanagan J, Kortegaard K, Pinder DN, Rades T, Singh H. Solubilisation of soybean oil in microemulsions using various surfactants. Food Hydrocolloids 2006; 20: 253-60.
95. Zhang Y, Gao J, Zheng H, Zhang R, Han Y. The preparation of 3, 5-dihydroxy-4-isopropylstilbene nanoemulsion and in vitro release. Int J Nanomed 2011; 6: 649-57.
96. Ishak K, Annuar MSM. Phase inversion of medium-chain-length poly-3-hydroxyalkanoates (mcl-PHA)-incorporated nanoemulsion: effects of mcl-PHA molecular weight and amount on its mechanism. Colloid Polym Sci 2016; 294: 1969-81.
97. Hörmann K, Zimmer A. Drug delivery and drug targeting with parenteral lipid nanoemulsions—A review. J Controlled Release 2016; 223: 85-98.
98. Puglia C, Rizza L, Drechsler M, Bonina F. Nanoemulsions as vehicles for topical administration of glycyrrhetic acid: characterization and in vitro and in vivo evaluation. Drug Deliv 2010; 17: 123-9.
99. Ee SL, Duan X, Liew J, Nguyen QD. Droplet size and stability of nano-emulsions produced by the temperature phase inversion method. Chem Eng J 2008; 140: 626-31.
100. Lovelyn C, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol 2011; 2: 626.
101. Gupta PK, Pandit J, Kumar A, Swaroop P, Gupta S. Pharmaceutical nanotechnology novel nanoemulsion-high energy emulsification preparation, evaluation and application. Pharma Res 2010; 1: 117-38.
102. Qian C, McClements DJ. Formation of nanoemulsions stabilized by model food-grade emulsifiers using high-pressure homogenization: factors affecting particle size. Food Hydrocolloids 2011; 25: 1000-8.
103. Gorain B, Choudhury H, Kundu A, Sarkar L, Karmakar S, Jaisankar P, Pal TK. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihyper-tensive activity in hypertensive rats. Colloids Surf B Biointerfaces 2014; 115: 286-94.
104. Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomed 2010; 5: 1595-616.
105. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev 2008; 60: 673-91.
106. Choudhury H, Gorain B, Karmakar S, et al. Improvement of cellular uptake, in vitro antitumor activity and sustained release profile with increased bioavailability from a nanoemulsion platform. Int J Pharm 2014; 460: 131-43.
107. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004; 278: 119-31.
108. Kang BK, Lee JS, Chon SK, et al. Development of selfmicroemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274: 65-73.
109. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25: 103-28.
110. Zhang J, Li J, Ju Y, Fu Y, Gong T, Zhang Z. Mechanism of enhanced oral absorption of morin by phospholipid complex based self-nanoemulsifying drug delivery system. Molr Pharm 2015; 12: 504-13.
111. Gao F, Zhang Z, Bu H, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Controlled Release 2011; 149: 168-74.
112. Anton N, Vandamme TF. Nano-emulsions and micro-emulsions: clarifications of the critical differences. Pharm Res 2011; 28: 978-85.
113. Sun D, Wei X, Xue X, et al. Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-α-tocopheryl polyethylene glycol 1000 succinate nanoemulsions. Int J Nanomed 2014; 9: 3413.
114. Lim H-T, Balakrishnan P, Oh DH, et al. Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs. Int J Pharm 2010; 397: 225-30.
115. Piao J, Lee J-E, Shin DH, Kim J-S. Pharmacokinetic study of mucoadhesive metformin pellets in rats. J Pharm Invest 2012; 42: 133-7.
116. Shen Q, Wang Y, Zhang Y. Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. Int J Nanomed 2011; 6: 1237-43.
117. Griffin BT, O'driscoll CM. A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid_based formulations in the anaesthetised rat model. J Pharm Pharmacol 2006; 58: 917-25.
118. Cho H, Salvia-Trujillo L, Kim J, Park Y, Xiao H, McClements D. Droplet size and composition of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10. Food Chem 2014; 156: 117-22.
119. Belhaj N, Dupuis F, Arab-Tehrany E, et al. Formulation, characterization and pharmacokinetic studies of coenzyme Q 10 PUFA’s nanoemulsions. Eur J Pharm Sci 2012; 47: 305-12.
120. Ozturk B, Argin S, Ozilgen M, McClements DJ. Nanoemulsion delivery systems for oil-soluble vitamins: influence of carrier oil type on lipid digestion and vitamin D 3 bioaccessibility. Food Chem 2015; 187: 499-506.
121. Armand M, Pasquier B, André M, et al. Digestion and absorption of 2 fat emulsions with different droplet sizes in the human digestive tract. Am J Clin Nutr 1999; 70: 1096-106.
122. Guttoff M, Saberi AH, McClements DJ. Formation of vitamin D nanoemulsion-based delivery systems by spontaneous emulsification: factors affecting particle size and stability. Food Chem 2015; 171: 117-22.
123. Doh H-J, Jung Y, Balakrishnan P, Cho H-J, Kim D-D. A novel lipid nanoemulsion system for improved permeation of granisetron. Colloids Surf B Biointerfaces 2013; 101: 475-80.
124. Sessa M, Balestrieri ML, Ferrari G, et al. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem 2014; 147: 42-50.
125. Monteiro LM, Lione VF, do Carmo FA, et al. Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int J Nanomed 2012; 7: 5175.
126. Gong Y, Wu Y, Zheng C, Fan L, Xiong F, Zhu J. An excellent delivery system for improving the oral bioavailability of natural vitamin E in rats. AAPS PharmSciTech 2012; 13: 961-6.
127. Dwivedi P, Khatik R, Chaturvedi P, et al. Arteether nanoemulsion for enhanced efficacy against Plasmodium yoelii nigeriensis malaria: An approach by enhanced bioavailability. Colloids Surf B Biointerfaces 2015; 126: 467-75.
128. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Effects of silymarin nanoemulsion against carbon tetrachlorideinduced hepatic damage. Arch pharm Res 2011; 34: 767-74.
129. Zhao H, Lu H, Gong T, Zhang Z. Nanoemulsion loaded with lycobetaine-oleic acid ionic complex: physicochemical characteristics, in vitro, in vivo evaluation, and antitumor activity. Int J Nanomed 2013; 8: 1959.
130. Pool H, Mendoza S, Xiao H, McClements DJ. Encapsulation and release of hydrophobic bioactive components in nanoemulsionbased delivery systems: impact of physical form on quercetin bioaccessibility. Food Function 2013; 4: 162-74.
131. Liu Z, Zhang Q, Ding L, et al. Preparation procedure and pharmacokinetic study of water-in-oil nanoemulsion of Panax notoginseng saponins for improving the oral bioavailability. Curr Drug Deliv 2016; 13: 600-10.
132. Zhou J, Zhou M, Yang F-F, et al. Involvement of the inhibition of intestinal glucuronidation in enhancing the oral bioavailability of resveratrol by labrasol containing nanoemulsions. Molr Pharm 2015; 12: 1084-95.
133. Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S_SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 2003; 92: 2386-98.
134. Woo JS, Lee CH, Shim CK, Hwang S-J. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 2003; 20: 24-30.
135. Rajpoot P, Bali V, Pathak K. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Int J Pharm 2012; 426: 219-30.
136. Kotta S, Khan AW, Ansari SH, Sharma RK, Ali J. Anti HIV nanoemulsion formulation: optimization and in vitro-in vivo evaluation. Int J Pharm 2014; 462: 129-34.
137. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? 2009.
138. Goldman RD. Intranasal drug delivery for children with acute illness. Curr Drug Ther 2006; 1: 127-30.
139. Jain R, Patravale VB. Development and evaluation of nitrendipine nanoemulsion for intranasal delivery. J Biomed Nanotechnol 2009; 5: 62-8.
140. Pardridge WM. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm Sci Technol Today 1999; 2: 49-59.
141. Kumar M, Pathak K, Misra A. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Develop Indus Pharm 2009; 35: 387-95.
142. Yadav S, Gattacceca F, Panicucci R, Amiji MM. Comparative biodistribution and pharmacokinetic analysis of cyclosporine-A in the brain upon intranasal or intravenous administration in an oil-inwater nanoemulsion formulation. Molr Pharm 2015; 12: 1523-33.
143. Sood S, Jain K, Gowthamarajan K. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B Biointerfaces 2014; 113: 330-7.
144. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005; 57: 1640-65.
145. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001; 53: 3-22.
146. Kumar M, Misra A, Mishra A, Mishra P, Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008; 16: 806-14.
147. Hosny KM, Banjar ZM. The formulation of a nasal nanoemulsion zaleplon in situ gel for the treatment of insomnia. Exp Opin Drug Deliv 2013; 10: 1033-41.
148. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England J medicine 2004; 350: 896-903.
149. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev 2001; 50: 81-106.
150. Wong PT, Leroueil PR, Smith DM, et al. Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants. PloS one 2015; 10: e0126120.
151. Makidon PE, Nigavekar SS, Bielinska AU, et al. Characterization of stability and nasal delivery systems for immunization with nanoemulsion-based vaccines. J Aerosol Med Pulmonary Drug Deliv 2010; 23: 77-89.
152. Hamouda T, Chepurnov A, Mank N, et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccines 2010; 6: 585-94.
153. Hamouda T, Sutcliffe JA, Ciotti S, Baker JR. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin Vaccine Immunol 2011; 18: 1167-75.
154. Das SC, Hatta M, Wilker PR, et al. Nanoemulsion W 80 5EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012; 30: 6871-7.
155. Bielinska AU, Janczak KW, Landers JJ, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infection Immun 2007; 75: 4020-9.
156. Stanberry L, Simon J, Johnson C, et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W 80 5EC combined with approved seasonal influenza antigens. Vaccine 2012; 30: 307-16.
157. Araújo F, Kelmann R, Araujo B, Finatto R, Teixeira H, Koester L. Development and characterization of parenteral nanoemulsions containing thalidomide. Eur J Pharm Sci 2011; 42: 238-45.
158. Thiagarajan P. Nanoemulsions for drug delivery through different routes. Res Biotechnol 2011; 2.
159. Kuminek G, Kratz JM, Ribeiro R, Kelmann RG, de Araújo BV, Teixeira HF, Simões CM, Koester LS. Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm 2009; 378: 146-8.
160. Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: Nanoject. Int J Pharm 2008; 364: 119-26.
161. Ganta S, Sharma P, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in longcirculating nanoemulsion. J Drug Targeting 2010; 18: 125-33.
162. Sun X, Liu D, Li P, Xu W, Zhang N. Formulation and pharmacokinetics of the parenteral fat nanoemulsion of ubenimex. J Chin Pharm Sci 2011; 20: 483-92.
163. Mishra RK, Soni G, Mishra R. Nanoemulsion: A novel drug delivery tool.
164. Jing X, Deng L, Gao B, et al. A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel. Nanomed Nanotechnol Biol Med 2014; 10: 371-80.
165. Patel SK, Zhang Y, Pollock JA, Janjic JM. Cyclooxgenase-2 inhibiting perfluoropoly (ethylene glycol) ether theranostic nanoemulsions— in vitro study. PloS one 2013; 8: e55802.
166. Ferreira LM, Cervi VF, Gehrcke M, et al. Ketoprofen-loaded pomegranate seed oil nanoemulsion stabilized by pullulan: selective antiglioma formulation for intravenous administration. Colloids Surf B Biointerfaces 2015; 130: 272-7.
167. de Vries IJM, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-7.
168. TaikáLim Y, HyunáChung B. Multifunctional perfluorocarbon nanoemulsions for 19 F-based magnetic resonance and nearinfrared optical imaging of dendritic cells. Chem Commun 2009: 6952-4.
169. Yang Z, Teng Y, Wang H, Hou H. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation. Int J Pharm 2013; 447: 231-40.
170. Ngan CL, Basri M, Lye FF, Masoumi HRF, Tripathy M, Karjiban RA, Abdul-Malek E. Comparison of process parameter optimization using different designs in nanoemulsion-based formulation for transdermal delivery of fullerene. Int J Nanomed 2014; 9: 4375.
171. Kim JH, Ko JA, Kim JT, et al. Preparation of a capsaicin-loaded nanoemulsion for improving skin penetration. J Agricultural Food Chem 2014; 62: 725-32.
172. Khurana S, Jain N, Bedi P. Nanoemulsion based gel for transdermal delivery of meloxicam: physico-chemical, mechanistic investigation. Life Sci 2013; 92: 383-92.
173. Sandig AG, Campmany AC, Campos FF, Villena MM, Naveros BC. Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: development, characterization and in vivo evaluation. Colloids Surf B Biointerfaces 2013; 103: 558-65.
174. Kong M, Chen XG, Kweon DK, Park HJ. Investigations on skin permeation of hyaluronic acid based nanoemulsion as transdermal carrier. Carbohydrate Polym 2011; 86: 837-43.
175. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2010; 99: 21-50.
176. Akhter S, Jain GK, Ahmad FJ, Khar RK, Jain N, Khan ZI, Talegaonkar S. Investigation of nanoemulsion system for transdermal delivery of domperidone: ex-vivo and in vivo studies. Curr Nanosci 2008; 4: 381-90.
177. Alam MS, Ali MS, Alam N, Siddiqui MR, Shamim M, Safhi M. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invention Today 2013; 5: 8-12.
178. Alvarado H, Abrego G, Souto E, et al. Nanoemulsions for dermal controlled release of oleanolic and ursolic acids: in vitro, ex vivo and in vivo characterization. Colloids Surf B Biointerfaces 2015; 130: 40-7.
179. Giri T. Nanoarchitectured Polysaccharide-Based Drug Carrier for Ocular. Nanoarchitectonics Smart Deliv Drug Targeting 2016: 119.
180. Panwar A, Upadhyay N, Bairagi M, Gujar S, Darwhekar G, Jain D. Emulgel: a review. Asian J Pharm Life Sci ISSN 2011; 2231: 4423.
181. Yu M, Ma H, Lei M, Li N, Tan F. In vitro/in vivo characterization of nanoemulsion formulation of metronidazole with improved skin targeting and anti-rosacea properties. Eur J Pharm Biopharm 2014; 88: 92-103.
182. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnol 2008; 6: 8.
183. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro-and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010; 7: 781-94.
184. Kayat J, Gajbhiye V, Tekade RK, Jain NK. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomed Nanotechnol Biol Med 2011; 7: 40-9.
185. Maheshwari RG, Tekade RK, Sharma PA, et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm J 2012; 20: 161-70.
186. Thakur S, Tekade RK, Kesharwani P, Jain NK. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J Nanoparticle Res 2013; 15: 1625.
187. Youngren SR, Tekade RK, Gustilo B, Hoffmann PR, Chougule MB. STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. BioMed Res Int 2013; 2013.
188. Youngren SR, Tekade RK, Hoffmann PR, Chougule MB. Biocompatible nanocarrier mediated delivery of STAT-6 siRNA to cancer cells. In: ed.^eds. AACR 2013.
189. Sessa M, Tsao R, Liu R, Ferrari G, Donsì F. Evaluation of the stability and antioxidant activity of nanoencapsulated resveratrol during in vitro digestion. J Agricultural Food Chem 2011; 59: 12352-60.
190. Ma Y, Li H, Guan S. Enhancement of the oral bioavailability of breviscapine by nanoemulsions drug delivery system. Drug Develop Indus Pharm 2015; 41: 177-82.
191. Chavhan SS, Petkar KC, Sawant KK. Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies. J Microencapsul 2013; 30: 771-9.
192. Zhang Z, Huang J, Jiang S, et al. A high_drug_loading self_assembled nanoemulsion enhances the oral absorption of probucol in rats. J Pharm Sci 2013; 102: 1301-6.
193. Pangeni R, Sharma S, Mustafa G, Ali J, Baboota S. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress. Nanotechnology 2014; 25: 485102.
194. Bahadur S, Pathak K. Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation. Curr Drug Deliv 2012; 9: 596-607.
195. Mustafa G, Ahuja A, Al Rohaimi AH, et al. Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization. Exp Rev Neurotherapeut 2015; 15: 695-710.
196. Wang SH, Fan Y, Makidon PE, Cao Z, Baker JR. Induction of immune tolerance in mice with a novel mucosal nanoemulsion adjuvant and self-antigen. Nanomedicine 2012; 7: 867-76.
197. Ragelle H, Crauste-Manciet S, Seguin J, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 2012; 427: 452-9.
198. Sa F, Zhang LQ, Chong CM, et al. Discovery of novel anti-Parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett 2015; 593: 7-12.
199. Schwarz JC, Weixelbaum A, Pagitsch E, Low M, Resch GP, Valenta C. Nanocarriers for dermal drug delivery: influence of preparation method, carrier type and rheological properties. Int J Pharm 2012; 437: 83-8.
200. Sallam MA, Marin Bosca MT. Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication. Int J Nanomed 2015; 10: 4459-78.